AstraZeneca reports Sone-Ve survival data; AstraZeneca stock costs EUR 153.53
Published on 10/25/2026 at 17:24 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWSSurvival results and next session
- AstraZeneca reported a 42 percent reduction in risk of death on October 25, 2026.
- AstraZeneca stock trades in weekend trading at Lang & Schwarz at EUR 153.53 at 5:22 p.m. CEST on October 25, 2026.
- The next Xetra session is scheduled for October 26, 2026.
AstraZeneca reported positive overall-survival results for sonesitatug vedotin, or Sone-Ve, in the CLARITY-Gastric01 Phase III trial on October 25, 2026, according to the company’s AstraZeneca. Separately, the stock was at EUR 153.53 in weekend trading at Lang & Schwarz at 5:22 p.m. CEST on October 25, 2026.
In a planned interim analysis, Sone-Ve reduced the risk of death by 42 percent versus investigator’s choice of therapy in the overall trial population. Median overall survival was 10.6 months with Sone-Ve compared with 6.4 months for the comparator arm, the company said.
Weekend trading
Lang & Schwarz quoted AstraZeneca at EUR 153.53 at 5:22 p.m. CEST on October 25, 2026. Xetra and the primary exchanges were closed during the weekend trading session. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of AstraZeneca stock.
Company development
The CLARITY-Gastric01 trial enrolled patients with locally advanced or metastatic gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma whose tumors expressed Claudin 18.2 on at least 25 percent of tumor cells. In the third-line and later setting, Sone-Ve reduced the risk of death by 53 percent, while median overall survival was 10.0 months versus 5.0 months for investigator’s choice of therapy, according to the company release.
Market context: Market report FTSE 100.
Dates ahead
The next Xetra session is scheduled for October 26, 2026. AstraZeneca’s reported ESMO presentation of the CLARITY-Gastric01 results took place on October 25, 2026, in Madrid, according to the company release.
